Skip to main content
  • Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia® Atrial Shunt in Large Segment of Heart Failure Patients

    REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy 

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details